Senju Pharmaceutical Co., Ltd.

Taiho Pharmaceutical Company Limited

Other

Takeda Chemical Industries, Inc.

Mitsubishi Chemical Corporation

Otsuka Pharmaceutical Company, Limited

Tanabe Seiyaku Company, Limited

A. H. Robins Company, Incorporated

Senju Pharmacuetical Co., Ltd.

Takahiro Ogawa

Noriko Watanabe

Takaaki Deguchi

Mitsunori Waki

Satoshi Yamashita

Yoshifumi Ikejiri

Fuminori Tokumochi

Yoshikazu Kuribayashi

Tadashi Terai

Motoko Kimura

Christopher Norbert Johnson

Kazumi Ogata

Steven Howard

Takahiro Sakaue

Keiji Kubo

Tadashi Shimamura

James Edward Harvey Day

Ryo Kato

Katsuhiro Inada

Takashi Mita

Jeffrey David St Denis

Akira Ohtori

Yujiro Yamamoto

Kazumichi Ushio

Yasushi Morita

Hideya Komatani

Yoshinori Ii

Shogo Sameshima

Shinichi Yasueda

Toshiharu Tsuboi

Hitoshi Ohmori

John Walter Liebeschuetz

Hideki Tokushige

Yasushi Okumura

Yufu Sagara

Shigeru Honda

Risako Miura

Mitsuyoshi Isaka

Atsushi Okumura

James Edward Day

The invention provides a compound of formula (I):

Heterobicyclic compounds for inhibiting the activity of SHP2

The present invention provides a compound represented by Formula (I) or a salt thereof; an LSD1 inhibitor that contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition that contains the compound or a salt thereof; and an antitumor agent that contains the compound or a salt thereof as an active ingredient.

Biphenyl compound or salt thereof

A compound or a salt thereof represented by Formula (I). An LSD1 inhibitor containing the compound or a salt thereof as an active ingredient. A pharmaceutical composition containing the compound or salt thereof. An antitumor agent containing the compound or a salt thereof as an active ingredient.

Drugs for ameliorating ocular circulatory disorders

In order to promote solubilization or suspension of 4-oxo-8-&lsqb;4-(4-phenylbutoxy)benzoylamino&rsqb;-2-(tetrazol-5-yl)-4H-1-benzopyran or its hydrate (pranlukast) in water, at least one component selected from surfactants, water-soluble cellulose derivatives and water-soluble vinyl polymers is formulated together with pranlukast. Thus, it is possible to provide an aqueous liquid pharmaceutical composition containing higher concentration of pranlukast and having good properties.

Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative

A pharmaceutical composition for preventing or treating visual function disorders caused by ocular circulatory disorders (for example, ocular hypertension and glaucoma) and visual function disorders based on ciliary tension (for example, myopia) whose active component is a vasopressin antagonist.

Preventives or remedies for vision disorders

A method for controlling axial length, comprising administering a pharmaceutically effective amount of a TGF-.beta. regulating substance. More particularly, a method for inhibiting axial elongation and a method for the prophylaxis and treatment of myopia, both comprising administering a TGF-.beta. activator, specifically a plasminogen activator. A method for elongation of axial length and a method for the prophylaxis and treatment of hyperopia, both comprising administering a TGF-.beta. activation inhibitor, particularly a plasminogen activator inhibitor. The method for controlling axial length of the present invention is extremely useful for the prophylaxis and treatment of myopia or hyperopia. It is also useful for preparing experimental model animals having eyes with complete axial myopia or hyperopia exclusive of refractive myopia or hyperopia.

Method for controlling axial length of the eye

An agent for the prophylaxis and treatment of disturbance of visual function, which comprises a compound of the formula �I! ##STR1## wherein A ring is optionally substituted;

Agent for prophylaxis and treatment of disturbance of visual function

A pharmaceutical composition comprising a stem cell factor (SCF) is administered systemically or locally, preferably administered locally to the eye surface to promote the healing of corneal disorder or injured part in comparison with untreated control.

Composition for treating cornea

There is disclosed a pharmaceutical composition for preventing or treating dry eye or a disease caused therefrom which comprises as an active ingredient an effective amount of sulfodehydroabietic acid or a pharmacologically acceptable salt thereof. There are also disclosed a method and device for preventing or treating dry eye or a disease caused therefrom.

Method for preventing or treating dry eye or disease caused therefrom

Pharmaceutical composition for use in glaucoma treatment

The present invention provides an ophthalmic preparation for reducing intraocular pressure comprising 2-[3-dimethyl-amino-2-(2-carboxyethoxy)propionyloxy]-2'-methoxybibenzyl or a salt thereof, which preparation exhibits intraocular pressure reducing activity, without exerting effects on the central nervous system, and can advantageously be used as a prophylactic and therapeutic agent for ocular hypertension and glaucoma bringing about elevated intraocular pressure.

Ophthalmic preparations for reducing intraocular pressure

This invention relates to an ocular hypotensive agent which comprises a compound represented by the formula: ##STR1## wherein R.sup.1 represents hydrogen or an optionally substituted hydrocarbon residue that may be bound via a hetero atom; R.sup.2 represents hydrogen or a hydrocarbon residue that may have a substituent; R.sup.3 represents a group capable of forming an anion or a group capable of changing thereto; X is a covalent bond between the 2 benzene rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n represents 1 or 2; ring A is a benzene ring having 1 or 2 optional substituents in addition to the group represented by COOR.sup.2, or a pharmaceutically acceptable salt thereof.

Ocular hypotensive agent

An ophthalmic suspension comprising difluprednate as an active ingredient. The ophthalmic suspension of the present invention shows superior antiinflammatory action and antiallergic action by local administration. Accordingly, the suspension of the present invention is useful for the treatment and prevention of disorders of the eye, such as allergic conjunctivitis, vernal conjunctivitis, blepharitis marginalis, catarrhal conjunctivitis and uveitis.

Ophthalmic suspension containing diflupredonate

An ophthalmic composition comprising a compound of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each a hydrogen, a halogen, a hydroxyl, a lower alkyl or a lower alkoxy, R.sup.3 and R.sup.4 are each a hydrogen, an optionally substituted lower alkyl, an optionally substituted cycloalkyl or an optionally substituted aralkyl, or form, together with the adjacent nitrogen atom, an optionally substituted ring, X is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally esterified or amidized carboxyl, Y is &gt;C.dbd.O or &gt;CH--OR.sup.5 wherein R.sup.5 is a hydrogen, an acyl or an optionally substituted carbamoyl, m is an integer of from 0 to 2, and n is an integer of from 1 to 6, or a salt thereof, and a method for the treatment of glaucoma, comprising administering said compound or a salt thereof.

Ophthalmic composition for lowering intraocular pressure

Growing community of inventors

Nishinomiya, Japan

Takahiro Ogawa